Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is seeking a Director, Clinical Research to provide clinical leadership in developing RNAi therapeutics across neurology and hematology therapeutic areas. The role involves leading clinical study efforts for the plasminogen program transitioning from Phase 2 to Phase 3, driving clinical development strategies, and ensuring operational excellence. The position requires collaboration with internal teams and external experts to achieve global regulatory approvals.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Alnylam Pharmaceuticals.